Positive News SentimentPositive NewsNASDAQ:CERE Cerevel Therapeutics (CERE) Stock Price, News & Analysis → Major Elon Musk Crypto Leak Revealed (From Crypto 101 Media) (Ad) Free CERE Stock Alerts $42.27 -0.11 (-0.26%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$42.11▼$42.3850-Day Range$40.88▼$43.2752-Week Range$19.59▼$43.59Volume1.06 million shsAverage Volume1.59 million shsMarket Capitalization$7.68 billionP/E RatioN/ADividend YieldN/APrice Target$41.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial Media Get Cerevel Therapeutics alerts: Email Address Cerevel Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.20 Rating ScoreUpside/Downside2.1% Downside$41.40 Price TargetShort InterestBearish8.00% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$4.30 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.53) to ($2.65) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.30 out of 5 starsMedical Sector914th out of 938 stocksPharmaceutical Preparations Industry413th out of 425 stocks 1.1 Analyst's Opinion Consensus RatingCerevel Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 2 buy ratings, 8 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $41.40, Cerevel Therapeutics has a forecasted downside of 2.1% from its current price of $42.27.Amount of Analyst CoverageCerevel Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.00% of the float of Cerevel Therapeutics has been sold short.Short Interest Ratio / Days to CoverCerevel Therapeutics has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Cerevel Therapeutics has recently decreased by 1.97%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCerevel Therapeutics does not currently pay a dividend.Dividend GrowthCerevel Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CERE. Previous Next 2.7 News and Social Media Coverage News SentimentCerevel Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Cerevel Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for CERE on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Cerevel Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cerevel Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,302,367.00 in company stock.Percentage Held by InsidersOnly 5.10% of the stock of Cerevel Therapeutics is held by insiders.Percentage Held by Institutions87.73% of the stock of Cerevel Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cerevel Therapeutics are expected to decrease in the coming year, from ($2.53) to ($2.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cerevel Therapeutics is -16.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cerevel Therapeutics is -16.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCerevel Therapeutics has a P/B Ratio of 11.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressA lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. Click here to jump in on the next one About Cerevel Therapeutics Stock (NASDAQ:CERE)Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.Read More CERE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CERE Stock News HeadlinesMarch 16, 2024 | insidertrades.comN Anthony Coles Sells 50,000 Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) StockMarch 16, 2024 | finance.yahoo.comCERE Apr 2024 40.000 callMarch 28, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…March 7, 2024 | markets.businessinsider.comCerevel Therapeutics: Hold Rating Amidst Pending AbbVie AcquisitionMarch 6, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Perspective Therapeutics (CATX)March 6, 2024 | seekingalpha.comCerevel Therapeutics: Parkinson's Could Be The IssueFebruary 28, 2024 | markets.businessinsider.comMaintaining Hold Rating Amid ABBV-CERE Deal Progress and Rising Operational CostsFebruary 24, 2024 | uk.finance.yahoo.comABBV Mar 2024 182.500 callMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.February 23, 2024 | bloomberg.comUS Politicians Raise Concerns Over Capital One-Discover DealFebruary 23, 2024 | uk.finance.yahoo.com3M Healthcare Unit Solventum Joins $53 Billion US Corporate Bond Sales SpreeFebruary 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Intra-Cellular Therapies (ITCI)February 22, 2024 | finance.yahoo.comAbbVie Selling $15 Billion Bonds to Buy ImmunoGen, CerevelFebruary 21, 2024 | reuters.comAbbVie eyes selling at least $13 bln of bonds to fund M&A, Bloomberg reportsFebruary 21, 2024 | finance.yahoo.comAbbVie (ABBV) Announces Appointment of New CEO Robert MichaelFebruary 16, 2024 | seekingalpha.comWall Street Breakfast Podcast: OpenAI's Text-To-Video AI ModelFebruary 16, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Corcept Therapeutics (CORT), Bio-Rad Laboratories (BIO)February 14, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE) and Roivant Sciences (ROIV)February 12, 2024 | msn.comAbbVie Cuts Its Guidance on ImmunoGen DealFebruary 5, 2024 | msn.comAbbVie’s full year 2023 sees a 6.4% net revenue dropFebruary 3, 2024 | investing.comCerevel Therapeutics Holdings Inc (CERE)February 3, 2024 | es-us.finanzas.yahoo.comAbbVie Reports Full-Year and Fourth-Quarter 2023 Financial ResultsFebruary 3, 2024 | morningstar.comAbbVie 4Q Sales Lower as Humira Revenue SinksFebruary 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX) and Regeneron (REGN)January 26, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Karuna Therapeutics (KRTX) and Health Catalyst (HCAT)January 24, 2024 | finance.yahoo.comTop Picks 2024- Celldex Therapeutics CLDXJanuary 24, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Sensus Healthcare (SRTS), Outlook Therapeutics (OTLK) and Leap Therapeutics (LPTX)See More Headlines Receive CERE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cerevel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2023Today3/28/2024Next Earnings (Estimated)4/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryCoal & Consumable Fuels Current SymbolNASDAQ:CERE CUSIP15677310 CIK767884 Webceres.net Phone844-304-2048FaxN/AEmployees334Year FoundedN/APrice Target and Rating Average Stock Price Target$41.40 High Stock Price Target$45.00 Low Stock Price Target$30.00 Potential Upside/Downside-2.3%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-432,840,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-100.14% Return on Assets-44.51% Debt Debt-to-Equity Ratio0.50 Current Ratio10.92 Quick Ratio10.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.71 per share Price / Book11.42Miscellaneous Outstanding Shares181,580,000Free Float172,316,000Market Cap$7.69 billion OptionableOptionable Beta1.49 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. N. Anthony Coles Jr. (Age 64)M.P.H., Executive Chairman Comp: $1.14MMr. Mark Bodenrader (Age 51)VP of Finance & Chief Accounting Officer Comp: $496.17kDr. John J. Renger Ph.D. (Age 55)Chief Scientific Officer Comp: $779.75kDr. Ramiro Sanchez M.D. (Age 63)Chief Medical Officer Comp: $805.13kMr. Ronald C. Renaud Jr. (Age 55)M.B.A., President, CEO & Director Dr. Susan Altschuller M.B.A. (Age 42)Ph.D., Chief Financial Officer Mr. Matthew CalistriVice President of Investor RelationsMr. Scott M. Akamine J.D. (Age 39)Chief Legal Officer & Corporate Secretary Comp: $444.74kMr. Kenneth A. DiPietro (Age 65)Chief Human Resources Officer Ms. Kathleen Tregoning M.A. (Age 53)Chief Corporate Affairs Officer Comp: $600.79kMore ExecutivesKey CompetitorsElanco Animal HealthNYSE:ELANJazz PharmaceuticalsNASDAQ:JAZZCytokineticsNASDAQ:CYTKViking TherapeuticsNASDAQ:VKTXRoivant SciencesNASDAQ:ROIVView All CompetitorsInsiders & InstitutionsPNC Financial Services Group Inc.Sold 3,006 shares on 3/22/2024Ownership: 0.004%Vanguard Group Inc.Bought 1,003,594 shares on 3/11/2024Ownership: 4.062%Wellington Management Group LLPSold 12,182 shares on 3/5/2024Ownership: 0.020%N Anthony ColesSold 50,000 sharesTotal: $2.05 M ($41.01/share)Goldman Sachs Group Inc.Bought 208,258 shares on 3/1/2024Ownership: 0.294%View All Insider TransactionsView All Institutional Transactions CERE Stock Analysis - Frequently Asked Questions Should I buy or sell Cerevel Therapeutics stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cerevel Therapeutics in the last twelve months. There are currently 8 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CERE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CERE, but not buy additional shares or sell existing shares. View CERE analyst ratings or view top-rated stocks. What is Cerevel Therapeutics' stock price target for 2024? 10 analysts have issued 1-year price objectives for Cerevel Therapeutics' shares. Their CERE share price targets range from $30.00 to $45.00. On average, they anticipate the company's share price to reach $41.40 in the next twelve months. This suggests that the stock has a possible downside of 2.1%. View analysts price targets for CERE or view top-rated stocks among Wall Street analysts. How have CERE shares performed in 2024? Cerevel Therapeutics' stock was trading at $42.40 at the start of the year. Since then, CERE shares have decreased by 0.3% and is now trading at $42.27. View the best growth stocks for 2024 here. When is Cerevel Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024. View our CERE earnings forecast. How were Cerevel Therapeutics' earnings last quarter? Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) posted its quarterly earnings results on Wednesday, November, 1st. The biotechnology company reported ($0.61) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.02. During the same quarter in the prior year, the company earned ($0.66) earnings per share. What ETFs hold Cerevel Therapeutics' stock? ETFs with the largest weight of Cerevel Therapeutics (NASDAQ:CERE) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), iShares Neuroscience and Healthcare ETF (IBRN) and Principal Healthcare Innovators ETF (BTEC).Harbor Health Care ETF (MEDI). What other stocks do shareholders of Cerevel Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cerevel Therapeutics investors own include Precigen (PGEN), Arena Pharmaceuticals (ARNA), CTI BioPharma (CTIC), Achillion Pharmaceuticals (ACHN), Alpha Natural Resources (ANRZQ), Cenveo (CVO), Hess (HES), Palatin Technologies (PTN), Aeterna Zentaris (AEZS) and Avid Bioservices (CDMO). Who are Cerevel Therapeutics' major shareholders? Cerevel Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Bain Capital Investors LLC (36.43%), Perceptive Advisors LLC (6.04%), Avoro Capital Advisors LLC (4.19%), Vanguard Group Inc. (4.09%), Vanguard Group Inc. (4.06%) and FIL Ltd (1.53%). Insiders that own company stock include Abraham Ceesay, Bain Capital Investors Llc, Deval L Patrick, Gabrielle Sulzberger, John Renger, Kenneth Dipietro, Marijn E Dekkers, Mark Bodenrader, N Anthony Coles, Paul D Burgess, Perceptive Advisors Llc, Ramiro Sanchez, Ronald C Renaud Jr, Scott Akamine and Susan Altschuller. View institutional ownership trends. How do I buy shares of Cerevel Therapeutics? Shares of CERE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CERE) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyInvestors Alert: The Next Big Thing in Weight LossBehind the MarketsMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerevel Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.